QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea

Bayer

Overview

This study is to describe the quality of life of Korean patients with early relapsing-remitting multiple sclerosis during the initial 1 year of treatment with Betaferon with several validated questionnaires.

Study Type

OBSERVATIONAL

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)DRUG

Patients receiving Betaferon according to routine clinical practice

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Relapsing-remitting MS (RRMS) patients within the first two years after diagnosis according to Poser or McDonald criteria, starting Betaferon treatment, including patients switching from other DMDs * Patients who signed informed consent form Exclusion Criteria: * Age lower than 18

Locations (1)

Unnamed facility

Many Locations, South Korea

Outcomes

Primary Outcomes

Quality of life evaluated by several validated questionnaire

Time frame: Baseline, 3, 6, 9, 12 months (+/- 1 month)

Secondary Outcomes

Information about safety of Betaferon in routine clinical use

Time frame: Baseline, 3, 6, 9, 12 months (+/- 1 month)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.